![]() ![]() Novel Coronavirus (Covid-2019), which first appeared in December 2019 in the Chinese city of Wuhan. Along with this, biological reductionism is revived fuelling simplified understandings of the genotype phenotype relationship in terms of biology and the human dimension in a broader sense, as well as visions of achieving human perfection through novel biotechnologies. Moreover, rapid translation into products for the global health market is based on marketable views on health and disease that in turn affect basic research through, for example, funding policies and the research questions being asked. We conclude that the shift from diagnostic to predictive interpretation of data that comes along with integrative biology seems to escape the general and sometimes the experts' awareness. analysis, we highlight some chances, pitfalls, and biases of this sector from a bioscience ethics stance. Exploring strengths and weaknesses, as well as opportunities and threats by S.W.O.T. Prediagnostics and genomics-based analyses successfully entered the public domain more or less unfiltered, offering numerous business opportunities envisioning individuals to contribute to the health sector by providing biomaterial and data as well as by using technology, thus becoming participants and informed coproducers of health. This shift in scientific approach co-occurs with an era of biocapitalism characterized by markets for biomaterial (e.g., DNA, cells, and tissues) as exploitable resources, high-throughput technologies as tools, and "Big Data" as currency. In current biomedicine, omics technologies drive systems-oriented modes of research to achieve a more holistic and personalized view of health and disease. Finally, we forecast that cognitive systems in general and IBM Watson in particular, if properly implemented, can bring transformative and sustainable capabilities in healthcare far beyond the current ones. As an example, we describe the PPT-DAM implementation by the Benchmarking Improvement Program at the Seattle Children's Hospital. When applied together with the classic Experiment–Execute–Evaluate iterative methodology, we suggest PPT-DAM is an extremely powerful approach to deliver quality health services to super-customers and customers. We propose a strategic solution to this end: the PPT-DAM (People–Process–Technology empowered by Data, Analytics, and Metrics) approach. ![]() To offer superior quality service, healthcare organizations have to refocus on the needs, pains, and aspirations of their super-customers by enabling the customers. With patients as super-customers, there are valuable lessons to be learned from industry examples, such as Amazon and Uber. In contrast, the originally intended customers-providers, doctors, and nurses-have relatively lagged behind. The super-customers have been patients, enabled by unprecedented social practices, such as the ability to track one's physical activities, personal genomics, patient advocacy for greater autonomy, and self-governance, to name but a few. A “super-customer” in healthcare is the patient, sample size of n = 1, while “customers” are the providers of healthcare (e.g., doctors and nurses). The “revolution” has already happened in technology, but the bottlenecks have shifted to the social domain: Who can be empowered by Big Data? Who are the users and customers? In this review and innovation field analysis, we introduce the idea of a “super-customer” versus “customer” and relate both to 21st century healthcare. ![]() ![]() Healthcare is transforming with data-intensive omics technologies and Big Data. ![]()
0 Comments
Leave a Reply. |